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Introduction 
Drug delivery to or via skin has provided an effective route for local or systemic 
administration of therapeutically active agents. However, skin and in particular the 
stratum corneum provides an efficient protective barrier for drug absorption. 
Stratum corneum (horny layer) has a thickness of about 15-20 µm, and is a layer 
of compressed, overlapping keratinized cells that form a flexible, tough and 
coherent membrane. This layer contains dead cells with keratin filaments in a 
matrix of proteins with lipids and water-soluble substances. The thickness and 
penetration properties of the stratum corneum depend upon its hydration, which is 
normally around 20% water. 
Gels for dermatological use have several favorable properties such as being 
thixotropic, greaseless, easily spreadable, easily removable, emollient, 
nonstaining, compatible with several excipients, and water-soluble or miscible. 
Emulgels are emulsions, either of the oil-in-water or water-in-oil type, which are 
gelled by mixing with a gelling agent. They have a high patient acceptability since 
they possess the previously mentioned advantages of both emulsions and gels. 
Therefore, they have been recently used as vehicles to deliver various drugs to the 
skin (13). 
Hence, one of the major challenges facing formulation scientists is to enhance and 
improve drug absorption through this rather elaborated barrier. A useful approach 
for increasing percutaneous absorption of drugs is to employ penetration or 
permeation enhancers. 
The term penetration enhancer is applied to materials that have a direct effect on 
the permeability of the skin barrier. Some materials may act by a direct chemical 
action on the skin while others may not have a specific barrier effect. The latter 
may affect the solubility and/or dispersibility of the medicament and/or its 
delivery system (the vehicle) (51). 
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The active pharmaceutical ingredient this research deals with is Azithromycin, its 
trade name is Zithromax. 
This antibiotic is classified as a semi-synthetic macrolide antibiotic chemically 
related to erythromycin and clarithromycin (39).  
 Azithromycin differs from other macrolides in its azalide structure., a methylated 
nitrogen atom in the number 9a position on the macrolide lactone ring (39). 
       Acne vulgaris is a common skin disease that affects 85-100% of people at 
some time during their lives. It is characterized by noninflammatory follicular 
papules or comedones and by inflammatory papules, pustules, and nodules in its 
more severe forms. Acne vulgaris affects the areas of skin with the densest 
population of sebaceous follicles; these areas include the face, the upper part of the 
chest, and the back (53).  
 The pathogenesis of acne vulgaris is multifactorial. Four key factors are  
  responsible for the development of an acne lesion (53):  
1-Follicular epidermal hyperproliferation and hyperkeratinization.  
2-Excess sebum. 
3-Propionibacterium acnes. 
4- Inflammation. 
Propionibacterium acnes is a microaerophilic organism present in many acne 
lesions. Although, it has not been shown to be present in the earliest lesions of 
acne, the microcomedo, its presence in later lesions is almost certain. P acnes 
stimulates inflammation by producing proinflammatory mediators that diffuse 
through the follicle wall. Recent studies have shown that P acnes binds to the toll-
like receptor on monocytes and neutrophils (14).  
Binding of the toll-like receptor then leads to the production of multiple 
proinflammatory cytokines, including interleukin 12 (IL-12), interleukin 8 (IL-8), 
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and tumor necrosis factor (TNF). Hypersensitivity to P. acnes may also explain 
why some individuals develop inflammatory acne vulgaris (53).  
Topical antibiotics are mainly used for their role against P. acnes. They may also 
have anti-inflammatory properties. Topical antibiotics are not comedolytic, and 
bacterial resistance may develop to any of these agents. 
Commonly prescribed topical antibiotics include erythromycin and clindamycin 
alone or in combination with benzoyl peroxide. Clindamycin and erythromycin are 
available in a variety of topical agents. They may be applied once or twice a 
day(53). 
The more lipophilic antibiotics, such as minocycline, are generally more effective 
than tetracycline. Greater efficacy may also be due to less P. acnes resistance to 
minocycline. However, P. acnes resistance is becoming more common with all 
classes of antibiotics currently used to treat acne vulgaris. P. acnes resistance to 
erythromycin has greatly reduced its usefulness in the treatment of acne. Other 
antibiotics such as  azithromycin, is reportedly helpful.  
Achieving a desirable percutaneous absorption of drug molecule is a major 
concern in formulating dermatological products. The use of penetration enhancers 
could provide a successful mean for this purpose.  
Different formulations of topical gels shall be prepared, where gels with different 
penetration enhancers shall be investigated to study the effect of these  penetration 
enhancers on the permeability rate of the drug through a synthetic membrane in a 
Franz-type diffusion cells. 
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1.1- Human skin  
The term skin ( figure 1) is commonly used to describe the body covering of any 
animal but technically refers only to the body covering of vertebrates (animals that 
have a backbone). The skin has the same basic structure in all vertebrates, 
including fish, reptiles, birds, and humans and other mammals(52).  
The skin is essential to a person’s survival (27); 
1- It forms a barrier that helps prevent harmful microorganisms and chemicals 
from entering the body. 
2- It also prevents the loss of life-sustaining body fluids. 
3-  It protects the vital structures inside the body from injury and from the 
potentially damaging ultraviolet rays of the sun. 
4-  The skin also helps regulate body temperature, excretes some waste 
products. 
     5- It is an important sensory organ, it contains various types of specialized 
nerve cells responsible for the sense of touch. 
The skin is made up of two layers, the epidermis and the dermis. The epidermis, 
the upper or outer layer of the skin, is a tough, waterproof, protective layer, about 
90 percent of the cells in the epidermis are keratinocytes, named because they 
produce a tough, fibrous protein called keratin. This protein is the main structural 
protein of the epidermis, and it provides many of the skin’s protective properties. 
Keratinocytes in the epidermis are arranged in layers, with the youngest cells in 
the lower layers and the oldest cells in the upper layers (52).                                
The old keratinocytes at the surface of the skin constantly slough off. Meanwhile, 
cells in the lower layers of the epidermis divide continually, producing new 
keratinocytes to replace those that have sloughed off.  
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As keratinocytes push up through the layers of the epidermis, they age and, in the 
process, produce keratin. By the time the cells reach the uppermost layer of the 
epidermis, they are dead and completely filled with the tough protein. Healthy 
epidermis replaces itself in a neatly orchestrated way every month (1).  
Scattered among the keratinocytes in the epidermis are melanocytes, cells that 
produce a dark pigment called melanin. This pigment gives color to the skin and 
protects it from the sun’s ultraviolet rays. 
 The dermis, or inner layer, is thicker than the epidermis and gives the skin its 
strength and elasticity. The dermis or lower layer of the skin is richly supplied 
with blood vessels and sensory nerve endings.  
The dermis is a complex structure. It consists mainly of a dense network of 
structural protein fibers, collagen, reticulum, and elastin, embedded in a semigel 
matrix of mucopoly-saccharidic "ground substance" .  
It ranges from 0.1 to 0.5 cm in thickness, it also exhibits distinct layers, the finely 
structured, thin papillary layer adjacent to the epidermis and the coarse reticular 
layer, which is the main structural body of the skin of considerable importance, the 
microcirculation that sub serves the entire skin is located in the dermis.  
The dermis is also penetrated by a network of sensory nerves (pressure, 
temperature, and pain) and lymphatics (43,44,52).  
The healthy dermis is sparsely populated with cells. Fibroblasts, which synthesize 
the fibrous structural materials, are found here and there. 
One also finds mast cells, whose functions presumably include conversion of the 
carbohydrate secretions of the fibroblasts into the ground substance. 
These cells and Langerhans cells have been linked to the allergic responses of the 
skin. 
 7 
Melanocytes lie within and beneath the epidermal-dermal interface, these are 
irregularly distributed.  
They produce a pigment, melanin, which is deposited into neighboring 
keratinocytes through their dendritic projections, which are pinched off after 
puncturing a keratinocyte's cell wall. Pigment is continuously formed and 
deposited in brown-black skins in response to the presence of melanocyte 
stimulating hormone (MSH). 
The two layers of the skin are anchored to one another by a thin but complex layer 
of tissue, known as the basement membrane. This tissue is composed of a series of 
elaborately interconnecting molecules that act as ropes and grappling hooks to 
hold the skin together. Below the dermis is the subcutaneous layer, a layer of 
tissue composed of protein fibers and adipose tissue (fat). Although not part of the 
skin itself, the subcutaneous layer contains glands and other skin structures, as 
well as sensory receptors involved in the sense of touch, see figure 1. 
 
 
Figure 1: Model of the skin layers and composition (52). 
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1.2 - Stratum corneum 
The stratum corneum ("the horny layer") is the outermost layer of the epidermis, 
and comprises the surface of the skin. It is composed mainly of dead cells that lack 
nuclei. As these dead cells slough off, they are continuously replaced by new cells 
from the stratum germinativum (52). 
The stratum corneum is under continuous formation, cells replace from beneath 
those that are worn off the surface. 
A turnover of cells of the stratum corneum occurs about every 2 weeks in normal 
adults (6). 
The cell units that are eventually form the stratum corneum layer is therefore 
referred to as the germinal (proliferative) layer because, at least in humans, cell 
division occurs here exclusively.  
Mitosis begins an extraordinary process in which daughter cells are pushed up 
into the next-higher layer, the spinous layer, and from there they continue 
to migrate to the body's surface. During their transit the cells flatten acutely and 
inwardly synthesize the protein and lipid which determine the nature of the fully 
differentiated horny layer. Protegenesis begins in the basal layer, where protein 
strands are formed. As the cells progress through the epidermis to take positions in 
the stratum corneum, these strands become more numerous. Massed proteins of 
different kinds can be distinguished by the time the cells reach the granular layer. 
A darkly staining material, which gives the granular layer its characteristic 
appearance, is a basic protein, filagrin. It is believed to induce filament 
aggregation when released in one of the culminating events of formation of the 
cornified structure. Under the influence of filagrin, the individual helical strands 
are formed into multistranded fibers which also have helical geometries. These, in 
turn, are organized into complex bundles (a-keratin) (52). 
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The finished keratinocyte's intracellular space is packed mainly with this 
semicrystalline a-keratin.  
Keratin in the cells of the stratum corneum  helps keep the skin hydrated by 
preventing water evaporation. In addition, these cells can also absorb water, 
further aiding in hydration and explaining why humans and other animals 
experience finger and toe wrinkling (colloquially called "pruning") when 
immersed in water for prolonged period (52). 
The thickness of the stratum corneum varies according to the amount of protection 
and/or grip required by a region of the body. For example, the hands are typically 
used to grasp objects, requiring the palms to be covered with a thick stratum 
corneum. Similarly, the sole of the foot is prone to injury, and so it is protected 
with a thick stratum corneum layer ( figure 2). 
 
 
Figure 2: Stratum corneum structure (6).  
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1.3- Percutaneous absorption 
   Different factors can affect percutaneous absorption, some are mentioned bellow:  
1.3.1- Gender and Race is associated with obvious appearance differences 
human skin.  
There is little evidence that the skins of male and female differ in permeability 
in any consequential way, however, there are differences in permeability of skin 
across human races.  
While the horny layers of Caucasian and black skin are of equal thickness, the 
latter contains more cell layers and is more dense. As a consequence, black skin 
has proven to be several fold less permeable than white skin (27). 
1.3.2- Environmental factors may have different effects on healthy skin which 
affect permeability. Moisture has been recognized as a plasticizer of stratum 
corneum. 
This means that it reduces crystallinity in the internal regimes of the horny 
matrix. It has long been known that hydrated stratum corneum is more 
permeable than dry stratum corneum (27).  
 1.3.3- Skin temperature also influences permeability. There are both kinetic 
and physiological influences associated with temperature.  
Additionally, the perfusion of blood through the skin both in terms of amount 
and closeness of approach to the skin surface is determined by external 
temperature and an individual's immediate requirement to retain or release body 
heat to maintain the body's 37°C isothermal state. Since clearance into the 
systemic circulation is sensitive to blood flow patterns, the normal fluctuations 
in surface blood flow should influence the uptake of transdermally delivered 
chemicals (27). 
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1.3.4- Health state of the skin determines its physical and physiological 
condition and thus its permeability, broken skin, where the skin has a physically 
disrupted stratum corneum represents a high permeability state (27).  
1.3.5- Polar solutes may have their absorption increased by several log orders in 
broken skin while hydrophobic solutes pass through the intact stratum corneum 
with greater ease due to favorable partitioning (27).  
When a drug system is applied topically, the drug diffuses passively out of 
its carrier or vehicle and into the stratum corneum and the sebum-filled 
pilosebaceous gland ducts. Inward diffusive movement continues through 
the full thickness of the stratum corneum and ducts and into the viable 
epidermal and dermal strata. A concentration gradient is thus established 
across the skin up to the outer reaches of the skin's microcirculation in the 
dermal layer. The systemic circulation acts as a reservoir or "sinks" for 
the drug, and a near-zero concentration of the drug is maintained at the 
plane formed at the edge of the capillaries where the drug is passed into 
the general system and diluted (8). 
A flow diagram of the steps or events requisite to percutaneous absorption 
following application of a drug in a thin vehicle film is shown in Figure 3. 
The important kinetic processes of dissolution and diffusion within the 
vehicle layer have been added to processes already described to complete 
the drug delivery picture. Each step in the diagram is potentially rate 
   limiting, depending on the drug and how it interacts within its vehicle and 
     with the skin. 
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Figure 3: A schematic diagram showing the events for percutaneous absorption 
(27).  
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The process consists consecutively of distributing or partitioning events at strata 
interfaces and diffusive events through strata. Whether the transepidermal route or 
transfollicular route is followed depends on the relative affinities of the respective 
tissues for the drug, the fractional areas of the routes, and the ease of diffusion 
through the respective phases.  
Regardless of which pathway is followed, the drug must partition into and diffuse 
through underlying viable tissues to be effective. Note that the first kinetic event, 
dissolution, is eliminated as a rate-determining factor if the applied vehicle 
film contains the drug as a solution. 
Two principal absorption routes are identified (27):  
1- The trans-epidermal route, correspondent to diffusion directly across the stratum 
corneum. 
2- The trans-follicular route, corresponding to diffusion through the follicular pore.  
It is true that the stratum corneum is a source of high diffusional resistance for most 
compounds, and when it is broken, many drugs penetrate the residual tissue with 
ease, and thus in a sense, the stratum corneum is the barrier layer. Exceptions exist, 
however, and extremely hydrophobic chemicals have as much or more trouble 
passing across the viable tissues (5,7,8).  
We have come to know, for instance, that ointments can be used over open wounds 
safely, for their hydrocarbon constituents are not transported significantly across 
aqueous phases. Similarly, the full-thickness skin is considerably more 
impermeable to Octanol in diffucion experiments in vitro than is the stratum 
corneum alone. On the other hand, physical analysis indicates that corticosteroids 
breach the stratum corneum so slowly that clinical responses, which are seen 
promptly, may be due to follicular diffusion.  
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Because of the dense nature of the stratum corneum, values of diffusion coefficients 
in this tissue are 1000 times smaller than anywhere else in the skin. 
The partition coefficient also varies as the composition of the stratum corneum 
varies, up to a point, percutaneous absorption can be improved by chemically 
modifying and increasing hydrophobicity of drugs.  
1.4- Penetration enhancers 
   Different approaches are known to reduce the skin barrier properties like  
1- Physical approach which acts on the stratum corneum  by stripping and 
hydration. 
2- Chemical approach by synthesis of lipophilic analogs, delipidization of the 
stratum corneum and coadministration of skin penetration enhancer. 
3- Biochemical approach by the synthesis of bioconvertible prodrugs and 
coadministration of skin metabolism inhibitors (8). 
Penetration enhancers are substances which temporarily diminish the 
impermeability of the skin, such material can be used clinically to enhance the 
penetration rate of drugs. 
Attributes for ideal penetration enhancer (3): 
1- The material shall be pharmacologically inert. 
2-  The material shall not affect the skin normal barrier properties upon 
removal. 
3- The material shall not cause losses of body fluids or any endogenous 
material. 
4-  The material shall not be toxic, allergic or irritating. 
5- It shall be compatible with other ingredients in the formula. 
6- The action of this material shall be predictable.  
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Classification of penetration enhancers (7,8): 
1- Ionic surfactants such as sodium lauryl sulphate, sodium laurate, sodiun 
dodecyl sulphate (SDS), and dioctyl sodium sulfosuccinate.  
2- Non ionic surfactants such as polyoxyethylene sorbate (Tween 80) and 
polyoxyethylene 9 lauryl ether (PLE). 
3- Bile salts and derivatives such as sodium glycocholate, sodium 
deoxycholate and sodium glycodihydrofusidate. 
4- Fatty acids and derivatives such as oleic acid, caprylic acid and luric acid. 
5- Sulfoxides such as DMSO. 
6- Polyols such as propylene glycol, polyethylene glycol and glycerol. 
7- Chelating agents such as EDTA. 
8- Monohydric alcohols such as ethanol and isopropyl alcohol. 
9- Others like urea , azone ( 1-dodecylazacycloheptane-2-one), cyclodextrin, 
terpenes and liposomes. 
 
1.5- Modes of action of skin penetration enhancers (8,12,27) :  
The action of penetration enhancers can be simplified as follows: 
1- Disruption of the stratum corneum lipids, enhancers may disrupt the polar head 
groups of the lipid bilayer, the aqueous region between the polar head groups and 
the lipophilic bilayer site in the non polar tail groups. 
For example, oleic acid can disrupt the structure of intercellular lipids because of 
its structure , also oleic acid can penetrate the skin but does not homogenously mix 
with the stratum corneum lipids, it shall exist as a pool of fluid within the stratum 
corneum leading to defects in the barrier function by providing an alternative 
penetration route.  
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Rigid packed lipid structure of long saturated  hydrocarbon chains are also 
disrupted by the incorporation of shorter saturated hydrocarbon chain or those 
with branched side chains, this will explain the optimum penetration enhancement 
for the C10-C12 unsaturated fatty acid and alcohols and justify why isostearic is 
better penetration enhancer than stearic acid., see figure 4 & 5 for explanation. 
2- Interaction with intercellular protein in the proteinaceous domain  which result 
in the swelling of the protein matrix and change in the keratin helices. 
3- Increased partitioning of the drug into the stratum corneum 
The partitioning coefficient of any drug determine its affinity to pass from the 
vehicle through the stratum corneum. 
In a case where the API have a very high affinity to the solvent and the solvent 
have a high penetratability to the skin then the portioning into and permeation 
through the skin can be increased by a solvent drug mechanism in which the drug 
and the solvent permeate together.   
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Figure 4: simplified diagram of skin structure and routes of drug penetration.  
(a):  Route (1) via the sweat ducts; route (2) across the continuous stratum 
corneum; or route (3) through the hair follicles with their associated sebaceous 
glands. (b) Representation of the stratum corneum membrane, illustrating two 
possible subroutes for diffusion.(c) Idealized representation of protein filaments in 
lipid matrix within stratum corneum cell (8). 
(b) and (c) routes can be clarified by Figure 5. 
 
 
Figure 5: Schematic representation of stratum corneum and its intercellular and 
transcellular pathways of drug permeation (27). 
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1.6- Topical Gel preparations 
Gels are semisolid systems in which a liquid phase is constrained within an 
interlocked, three-dimensional polymeric matrix of a natural or synthetic gum.  
The gelling polymer is normally present in low percentage concentration, certainly 
less than 10%, and usually on the order of 0.5 to 2.0%. Some of these systems are 
clear as water in appearance and visually aesthetically pleasing.  
Others are turbid, as the polymer is either not fully molecularly dissolved or forms 
aggregates, which disperse light.  
Gels are watery when warm but solidify near room temperature to form gels that 
are semisolid to rubbery, depending on the source and concentration of the gelling 
agent. 
 The gelling is not simply due to increased chain-chain entanglements; otherwise, 
the system would merely become viscid. Rather, the system sets up as the result of 
the entwining of the polymer ends into double helices, a crystallization 
phenomenon that fixes the polymeric strands in place, yielding a stable, yet 
deformable structure (11,16,17).  
The structure should persist to temperatures exceeding body temperature for such 
systems to be most topically useful. The polymers used to prepare pharmaceutical 
gels include natural gums such as tragacanth, pectin, carrageen, agar, and alginic 
acid, and synthetic and semisynthetic materials such as methylcellulose, 
hydroethylcellulose, carboxymethylcellulose, Polyacrylamide Iso- 
paraffin Laureth-7, and the Carbopols.   
Gels are used pharmaceutically as lubricants and as carriers for active 
pharmaceutical agents (26,27).  
The preparation of gels may involve a fusion process or may require a 
special procedure, depending on the gelling agent involved.  
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Tragacanth systems must be prepared at low temperature due to the extreme heat 
liability of this natural gum. On the other hand, it is easier to disperse methyl 
cellulose in hot than in cold water. The Carbopols are gelled by a unique 
procedure, the polymer is dispersed in an acidic medium, when the 
dispersion is uniform, gelling is induced by neutralizing the system with 
an inorganic base (aqueous systems) or with an amine such as triethanolamine. 
This ionizes the acidic functional groups on the polymer, drawing the polymer into 
colloidal solution, in which state it forms the requisite structural matrix. 
Several prototype gel formulations are available where the design of specific 
systems tailored to meet predetermined, demanding performance criteria, 
particularly with respect to bioavailability. 
1.7- Acne 
  Is an inflammatory disease of the skin, caused by changes in the pilosebaceous 
units (skin structures consisting of a hair follicle and its associated sebaceous 
gland). The most common form of acne is known as "acne vulgaris", which means 
common acne. Excessive secretion of oils from the glands combine with naturally 
occurring dead skin cells to block the hair follicles. Oil secretions build up beneath 
the blocked pore, providing a perfect environment for the skin bacteria 
Propionibacterium acnes to multiply uncontrolled. In response, the skin inflames, 
producing the visible lesion. The face, chest, back, shoulders and upper arms are 
especially affected (52,53). 
The typical acne lesions are: comedones, papules, pustules, nodules and 
inflammatory cysts. These are the more inflamed form of pus-filled or reddish 
bumps, even boil-like tender swellings. Non-inflamed 'sebaceous cysts', more 
properly called epidermoid cysts, occur either in asssociation with acne or alone 
but are not a constant feature. After resolution of acne lesions, prominent unsightly 
scars may remain. 
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The condition is common in puberty as a result of an abnormal response to normal 
levels of the male hormone testosterone. The response for most people diminishes 
over time and acne thus tends to disappear, or at least decrease, after one reaches 
about the age of thirty. There is, however, no way to predict how long it will take 
for it to disappear entirely, and some individuals will continue to suffer from acne 
decades later, into their thirties and forties and even beyond. 
1- Acne vulgaris is more common in males than in females during 
adolescence.  
2- It is more common in women than in men during adulthood.  
3- Three categories of legions formed during acne are non inflammatory 
legions, inflammatory lesions, and scars. 
4- Three non inflammatory legions include microcomedos Fig 6,                 
open comedos Fig.7, which have a central impaction of keratin and lipid 
and might or might not be slightly raised, and closed comedos Fig 8, which 
are slightly elevated papules that could possibly form into a larger 
inflammatory lesion (30). 
 
 
Figure 6: Microcomed structure (30). 
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Figure 7: Open comedo structure (30).  
 
Figure 8:  Closed comedo structure (30).  
5- Moderate inflammatory acne has Inflammatory legions include more 
aggravated legions such as pustules and large, fluctuant nodules. 
6- Nodulocystic acne is characterized by comedones, inflammatory lesions, 
and large nodules greater than 5 mm in diameter. Scarring is often evident. 
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 Acne can be treated at different levels (53):   
1- Topical and oral antibiotics treatment with the tetracyclines , clindamycin, 
erythromycin and Benzoyl peroxide topically. 
 
 
 
 
    Figure 9: Erythromycin A structure (52).  
 
Erythromycin prevents bacteria from growing, by interfering with their 
protein synthesis. Erythromycin binds to the subunit 50S of the bacterial 
ribosome, and thus inhibits the translation of peptides. 
 
Figure 10:  Benzoyl peroxide structure (52).   
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While it is not fully known how benzoyl peroxide works in fighting acne, it is 
presumed that benzoyl peroxide is easily absorbed into pores where it works by 
interfering with acne bacterial metabolism through oxidation.  
2- Systemic treatment with Vitamin E derivatives like Isotretinoin to reduce 
the secretion of oils from the glands  
3- Normalizing the follicle cell lifecycle by a group of medications like  
topical retinoids such as tretinoin (brand name Retin-A), adapalene (brand 
name Differin) and tazarotene (brand name Tazorac). 
4- Surgical treatment by exfoliating the skin. This can be done either 
mechanically, using an abrasive cloth or a liquid scrub, or chemically. 
Common chemical exfoliating agents include salicylic acid and glycolic 
acid, which encourage the peeling of the top layer of skin to prevent a build-
up of dead skin cells which combine with skin oil to block pores. 
5- Phototherapy using red light or blue light and photodynamic therapy are 
being assessed as potential treatments for acne. 
6- The usefulness of some laser treatments in the management of acne is also 
being evaluated. 
7- Hormonal treatments for females, acne can be improved with a combined 
oestrogen/progestogen contraceptive pill. Cyproterone brande name (Diane 
35 ) is particularly effective at reducing androgenic hormone levels and 
until recently was the best oral contaceptive treatment.  
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1.8 - Propionibacterium acne (14)  
   Table 1: Propionibacterium acne classifications                             
Kingdom Bacteria 
Phylum               Actinobacteria   
Order Actinomycetales 
Family Propionibacteriaceae 
Genus Propionibacterium 
Species P. acnes      
 
 
 
Figure 11:  Propionibacterium acnes. ( by courtsy of inflammation research center) 
(14).   
Description and Significance:  
Species of Propionibacteria can be found all over the body. Propionibacteria are 
generally nonpathogenic; however, when certain species of Propionibacteria 
contaminate blood and other body fluid, they can cause a number of infections 
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including the common skin disease acne vulgaris (caused by P. acnes). Some 
species of Propionibacteria are found in food like cheeses and other dairy 
products. P. freudenreichii is used in Swiss cheese manufacturing to produce its 
flavor and characteristic holes (14). 
 
Genome Structure:  
Currently there is one genome project that is complete on Propionibacterium acnes 
KPA1202 and there is one in progress on Nocardioides sp. JS324. The entire 
genome sequence of P. acnes encodes 2333 putative genes and revealed numerous 
gene products involved in degrading host molecules, including sialidases, 
neuraminidases, endoglycoceramidases, lipases, and pore-forming factors (14).  
Cell Structure and Metabolism: 
Propionibacteria are slow-growing, nonsporeforming, Gram-positive, anaerobic 
bacteria. They can be rod-shaped or branched and can occur singularly, in pairs, or 
in groups. They generally produce lactic acid, propionic acid, and acetic acid from 
glucose.  
 
1.9- Azithromycin  
 Description:  
Azithromycin is an azalide, a subclass of macrolide antibiotics, for oral 
administration. 
Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- 
13-[(2,6-dideoxy-3-C-methyl-3-O-methyl--L-ribo-hexopyranosyl)oxy]-2-ethyl-
3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
(dimethylamino)--D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-
one (39). 
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Azithromycin is derived from erythromycin; however, it differs chemically from 
erythromycin in that a methyl-substituted nitrogen atom is incorporated into the 
lactone ring. Its molecular formula is C38H72N2O12, and its molecular weight is 
749.00. 
 
 
 
Figure 12: Azithromycin structure (32).  
Azithromycin, as the dihydrate, is a white crystalline powder with a molecular 
formula of C38H72N2O122H2O and a molecular weight of 785.0. 
Pharmacokinetics: 
Following oral administration of a single 500 mg dose (two 250 mg tablets) to 36 
fasted healthy male volunteers, the mean (SD) pharmacokinetic parameters were 
AUC from 0-72 = 4.3 (1.2)  mcg ·h / ml; C max = 0.5 (0.2) mcg/ml; T max = 2.2 
(0.9) hours (39). 
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Absorption:  
The absolute bioavailability of azithromycin 250 mg capsules is 38%. 
Distribution:  
The serum protein binding of azithromycin is variable in the concentration range 
approximating human exposure, decreasing from 51% at 0.02 mcg/ml to 7% at 2 
mcg/ml. 
Following oral administration, azithromycin is widely distributed throughout the 
body with an apparent steady-state volume of distribution of 31.1 L/kg. Greater 
azithromycin concentrations in tissues than in plasma or serum were observed. 
High tissue concentrations should not be interpreted to be quantitatively related to 
clinical efficacy. The antimicrobial activity of azithromycin is pH related and 
appears to be reduced with decreasing pH. However, the extensive distribution of 
drug to tissues may be relevant to clinical activity (39). 
Metabolism:  
In vitro and in vivo studies to assess the metabolism of azithromycin have not 
been performed. 
Elimination:  
Plasma concentrations of azithromycin following single 500 mg oral and i.v. doses 
declined in a polyphasic pattern with a mean apparent plasma clearance of 630 
mL/min and terminal elimination half-life of 68 hours. The prolonged terminal 
half-life is thought to be due to extensive uptake and subsequent release of drug 
from tissues. 
Mechanism of action:  
 Azithromycin acts by binding to the 50S ribosomal subunit of susceptible 
Microorganisms and, thus, interfering with microbial protein synthesis, nucleic 
acid synthesis is not affected. 
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Biological activity:  
Azithromycin has been shown to be active against most isolates of the following 
microorganisms (39): 
1-Aerobic and facultative gram-positive microorganisms 
Staphylococcus aureus 
Streptococcus agalactiae 
Streptococcus pneumoniae 
Streptococcus pyogenes 
2-Aerobic and facultative gram-negative microorganisms 
Haemophilus ducreyi 
Haemophilus influenzae 
Moraxella catarrhalis 
Neisseria gonorrhoeae 
 
3-Other microorganisms 
Chlamydia pneumoniae 
Chlamydia trachomatis 
Mycoplasma pneumoniae 
Beta-lactamase production should have no effect on azithromycin activity. 
Indication and usage: 
Acute bacterial exacerbations of chronic obstructive pulmonary disease due to 
Haemophilus influenzae,  Moraxella catarrhalis or Streptococcus pneumoniae. 
Acute bacterial sinusitis due to Haemophilus influenzae,  Moraxella catarrhalis or 
Streptococcus pneumoniae. 
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Community-acquired pneumonia due to:  Chlamydia pneumoniae, Haemophilus 
influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients 
appropriate for oral therapy (14). 
Uncomplicated skin and skin structure infections due to Staphylococcus aureus, 
Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require 
surgical drainage. 
Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae.  
Genital ulcer disease in men due to Haemophilus ducreyi, (chancroid).  
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1.10- Modified Franz diffusion cell ( MFDC) 
Modified Franz diffusion cell as shown in Figure 12 is used for 
permeation studies as described bellow. 
 
 
 
Figure 13: Modified Franz Diffusion Cell (MFDC) (5).   
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 The cell is composed of 3 main parts (38): 
1- The donor compartment  
The donor compartment filled with the gel dosage form which contains the 
Azithromycin and a particular penetration enhancer (PE).  
2- The receiver compartment  
The receiver compartment was filled with degassed 30% Hydro alcoholic 
solution.  
3- The synthetic membrane  
      The synthetic membrane was mounted between the donor and the receiver 
compartments of the diffusion cell with effective surface area of 3 cm2. 
 At the junction of the donor and receiver compartments, the diffusion cell 
wrapped with a waterproof parafilm to prevent solution leakage during the 
diffusion experiment and connected tightly together using rubber ring and a metal 
clamp.  
In order to avoid the evaporation of the solvent from the donor compartment 
during the diffusion experiment, it is closed by waterproof parafilm. 
The diffusion experiment study lasted for 6 hours.  
The diffusion system especially the receiver compartment was kept at a 
temperature of 32 (temperature of the human skin) by using a water jacket.  
The receiver fluid was mixed continuously during diffusion experiment using a 
magnetic stirring at 500 rpm in order to keep  sink condition in the receiver media 
as is the case of blood circulation in the human body (27).  
Serial sampling from the receptor phase was performed for 6 hrs every O.5hr 
intervals and the amount of the absorbed drug was analyzed using high 
performance liquid chromatography (HPLC), or by a biological assay.  
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The cumulative amount of the permeated drug was plotted against time and the 
slope of the linear part of the graph (permeation flux) was measured, from which 
the permeability coefficient was calculated using first Fick's Law.  
 
1.11- Diffusion theory : 
"The amount of material M flowing through a unit cross section S of a barrier 
in unit time t is known as the flux, J  
J = d M / S . d t        ……………………….. 1 
The flux in turn is proportional to the concentration gradient, d C / d x  
J = -D (d C / d x )      ………………………...2  
In which D is the diffusion coefficient of a penetrant or diffusant  in cm2 / sec, 
C is concentration in g / cm3 , and x is the  distance  in cm of movement 
perpendicular to the surface of the barrier.  
In equation (1), the mass, M, is usually given in grams, the barrier surface, S, 
in cm2, and the time, t, in seconds.  
The negative sign of equation (2) signifies that diffusion occurs in a direction 
(the positive x direction) opposite to that of increasing concentration.  
That is to say, diffusion occurs in the direction of decreasing concentration of 
diffusant; thus, the flux is always a positive quantity. 
The diffusion constant, D, or diffusivity as it is often called, does not 
ordinarily remain constant, for it may change in value at higher 
concentrations.  
 
D is also affected by temperature, pressure, solvent properties, and the 
chemical nature of the diffusant. 
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Therefore, D is referred to more correctly as a diffusion coefficient rather than 
as a constant. 
Fick's second law represents the equation for mass transport that emphasizes 
the change in concentration with time at a definite location. 
This diffusion equation is derived as follows:  
The concentration C, in a particular volume element, (see Figures13),  
changes only as a result of net flow of diffusing molecules into or out of the 
region.  
A difference in concentration results from a difference in input and output. 
The concentration of diffusant in the volume element changes with time,                                  
i.e., d C / d t, as the flux or amount diffusing changes with distance,                       
d J / d x, in the x direction, or 
d c / d J = - d J / d x                ………………........3 
Differentiating the first law expression, equation (2), with respect to x, one 
obtains: 
 d J / d x = D ( d2C / d x2)     ………………………..4 
Substituting d C/ d t from equation (3) into equation (4) results in Fick's 
second law, namely 
d C /  d t = D ( d2C/ dx2)  ………………………………5 
Equation (5) represents diffusion only in the x direction. If one wishes to 
express concentration changes of diffusant in three dimensions, 
Fick's second law is written in the general form: 
d C/ dt = D ( d2C/dx2 + d2C/ dy2 + d2C/ dz2 )     …………..6  
This expression is not ordinarily needed in pharmaceutical problems of 
diffusion, however, since movement in one direction is sufficient to describe 
most cases. 
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 Fick's second law states that the change in concentration with time in a 
particular region is proportional to the change in the concentration gradient at 
that point in the system. 
Fick's first law, equation (2), gives the flux (or rate of diffusion through unit 
area) in the steady state of flow. The second law refers in general to a change 
in concentration of diffusant with time, at any distance, x, i.e., a non steady 
state of flow. 
Steady state may be described, however, in terms of the second law, equation 
(5).  
Consider the diffusant originally dissolved in a solvent in the left-hand 
compartment of the cell shown in Figure 14. Solvent alone is placed on the 
right-hand side of the barrier, and the solute or penetrant diffuses through the 
central barrier from solution to solvent side (donor to receptor compartment). 
In diffusion experiments, the solution in the receptor compartment is 
constantly removed and replaced with fresh solvent so as to keep the 
concentration at a low level.   
This is referred to as "sink conditions," the left compartment being the source 
and the right compartment the sink. 
Originally, the diffusant concentration will fall in the left compartment and 
rise in the right compartment until the system comes to an equilibrium, based 
on the rate of removal of the diffusant from the sink and the nature of the 
barrier.  
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Figure 14: Diffusion cell, donor and receiver compartments  
 
 
 
  
When the system has been in existence for a sufficient period of time,  the 
concentration of the diffusant in the solutions at the left and the right of the 
barrier become constant with respect to time, but obviously not the same in 
the two compartments.   
Then within each diffusional slice perpendicular to the direction of flow, the 
rate of change of concentration dC / dt, will be zero , and by the second law, C 
is the concentration of the permeant in the barrier expressed in mass/cm3. 
D C / d t = D ( d2C/ dx2) = 0   …………………………….7 
 Equation (7) demonstrates that since D is not equal to zero, 
d2C/d x2 = O.  
In other words, the concentration gradient across the membrane, 
dC/dx is constant, signifying a linear relationship between concentration, C, 
and distance x.  
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This is shown in Figure 15 (in which the distance x is equal to h) for drug 
diffusing from left to right in the cell of figure 13. 
 
 
 
 
 
 
Figure 15: Concentration gradient of diffusant across the diaphragm of a diffusion 
cell.   
The concentration will not be rigidly constant but rather is likely to vary 
slightly with time, and then dC / dt is not exactly zero.  
Fick adapted the two diffusion equations, (2) and (5), to the transport of 
matter from the laws of heat conduction.  
If a diaphragm separates the two compartments of a diffusion cell of cross-
sectional area S, and thickness h, and if the concentrations in the membrane 
on the left (donor) and on the right (receptor) sides are C 1 and C 2, 
respectively, (Figure14), the first law of Fick may be written: 
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J = d M/ S dt = D ( ( C1-C2) / h )     …………………………………..8  
 
in which (C1 -C2)/h approximates dC/dx. 
The concentrations C 1 and C 2 within the membrane ordinarily are not known 
but can be replaced by the partition coefficient multiplied by the concentration 
Cd on the donor side or Cr in the receiver side as follows. The distribution or 
partition coefficient, K, is given by 
K = C1/Cd = C2/Cr    …………………………………. 9  
Hence, 
d M/ dt = DSK ( Cd-Cr) / h    …………………………10 
and, if sink conditions hold in the receptor compartment, Cr nearly zero, then  
dM /dt =  DSKCd / h = PSCd     …………………………11 
in which 
P = D k / h   (cm / second)   ………………………….12 
It is noteworthy that the permeability coefficient, P, has units of linear velocity.  
In some cases, it is not possible to determine D, K, or h independently and 
thereby to calculate P, it is a relatively simple matter, however, to measure the 
rate of barrier permeation and to obtain the surface area S and concentration Cd 
in the donor phase and the amount of permeant M in the receiving sink. 
One can then obtain P from the slope of a linear plot of M/cm2 versus t: 
M = PSCdt        ………………………………13 
A constant-activity dosage form may not exhibit a steady-state process from the 
initial time of release. Figure15 is a plot of the amount of butylparaben penetrating 
through guinea pig skin from a dilute aqueous solution of the penetrant. It is 
observed that the curve of Figure 16 is convex to the time axis in the early stage and 
then becomes linear.  
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Figure 16: Butylparaben penetrating through guinea pig skin from a dilute aqueous 
solution of the penetrant.          
    
The early stage is the non steady-state condition. At later times, the rate of diffusion 
is constant, the curve is essentially linear, and the system is at steady state.  
 
When the steady-state portion of the line is extrapolated to the time axis, as 
shown in Figure 16, the point of intersection is known as the lag time,  TL.  
This is the time required for a penetrant to establish a uniform concentration 
gradient within the membrane separating the donor from the receptor compartments. 
In the case of a time lag, the straight line of Figure 15 may be represented by a 
modification of equation (10): 
 
C
m
2
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M = ( SDKCd / h )( t – t L )    ………………………………..14 
The lag time, t L, is given by 
TL = h2 / 6D          …………………………………………15 
and its measurement provides a means of calculating the diffusivity D, presuming a 
knowledge of the membrane thickness h.  
Also, knowing P, the thickness h can be calculated from 
TL = h K / 6P                                  ………………………. 16 
Diffusivity depends on the resistance to passage of a diffusing molecule" (38).  
 
Important equations : 
TL = intercept / slop, from M / S v s Time curve 
TL = h K / 6P 
D = h2 / 6 TL 
P = slop / concentration, from M / S v s Time curve  
P = D K / h  
K = P .h / D 
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Experimental part  
The main objective of this study is: 
1- Dissolving Azithromycin in a suitable solution that conserve stability over a 
certain period of time. 
2-Preparation of a gel structure,  containing a constant concentration (2% w/w) of 
the active pharmaceutical ingredient (API) and known concentration of each 
penetration enhancer. 
3- Study the permeability behavior of Azithromycin in the presence of different 
penetration enhancers using modified Franz diffusion cell through a synthetic 
membrane. 
3-Depending on the diffusion study, the most effective penetration enhancers will 
be selected to determine the final formula of the drug. 
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2.1- Materials  
Table 2: List of material used in the study  
                                           
No, Item  Source  
1 Azithromycin 
 
Pfizer company  
2 Bacteria  Micrococus luteus ATCC 
#9341 organism    
3 Carbomer 940 
 
Noveon / 1504G187A 
4 Cremophore Rh40 
 
BASF / 16428368E0 
5 Ethyl alcohol  
 
Pharmco / 6365 
6 IPM 
 
Industrial Quimisalase / 
309022 
7 Methyl paraben 
 
Clariant / GBGA029313 
8 Octanol   
 
Merck   
9 Oleic acid 
 
Merck  
10 Propylene Glycol 
 
Dow / SL271920D4 
11 Propyl paraben  
 
Clariant / GEGA023832 
12 Sepigel (Polyacrylamide, Iso- 
paraffin, Laureth-7). 
 
Seppic / T51215 
13 Tween 80  
 
Croda 2473 
14 Triethanolamine 
 
Merck  22006665 
15 Urea 
 
Riedel / 32270 
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2.2- Equipment  
Table 3: List of equipment used in the study 
No.   Equipment Source /    Model     
1 Computer Acer 
2 Incubator Tuttnawer 
3 Modified Franz diffusion cell Jordan University of science and 
technology work shop  
4 Microscope Leica 
5 Polyamide membrane  Sartolon polyamide -Germany, 
Pore size = 0.2mc.m. 
6 pH meter   Inolab 
7 Refrigerator Leonard 
8 Stirrer-Heater Fried 
9 Synthetic Membranes. dialysis membrane (32/32A, 0.2 
mc.m pores). 
10 UV/ HPLC. Unicam / Merck-Hitachi 
11 Viscometer Brook-Field  
12 Water bath and pump. Jolabo / Millipore 
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2.3- Methodology  
2.3.1-Solubilization of Azithromycin in a suitable solvent to obtain chemically and 
physically stable solution: 
 
Different solvents, co-solvents and combinations of them shall be tried such as  
purified water, ethyl alcohol, tween80 and propylene glycol taking into 
consideration that the solvent is acceptable for the formulation of topical 
dosage forms and attain stability of the API during the period of usage.  
 
     2.3.2- Preparation of the gel vehicle with the following characteristics. 
 
        1- Acceptable as a topical dosage form. 
        2- Non irritating to the skin. 
        3- Compatible with all ingredients forming the product.  
        4- Having a physically stable structure during the shelf life period. 
        5- Attain the API in soluble form during the period of treatment. 
        6- Keep the API stable during the period of treatment  
          
Different formulations were prepared as indicated below:  
   
Table 4:  Different trials of gel formulations 
 
Ingredient  Formula A Formula B Formula C 
Azithromycin (API) * * * 
Purified water ( Solvent)  * * * 
Ethyl alcohol ( Solvent)  *  
Tween 80( Polyoxy sorbate 80) 
(Solubilizer) 
*  * 
Cremophore RH40 ( Solubilizer)   * * 
Sepigel ( Gelling agent)  * * 
Carbomer ( gelling agent)  *   
Triethanolamine (alkalinizing agent  )  *   
Methyl paraben 0.1% (preservative )  * * * 
Propyl paraben 0.01% ( Preservative)    * * * 
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2.3.3- Formulations of Azithromycin gel containing different penetration 
enhancers.   The final gel structure that achieves the requirements are prepared 
with different penetration enhancers to run the permeability study and an ongoing  
shelf life stability study.  
The following formulations were prepared for further study: 
 
 
Table 5: Different trials of Azithromycin formulations with different penetration 
enhancers 
 
Ingredient  
 
F1 ( Balnk ) F2 F3 F4 F5 
Gel vehicle  98% 88% 88% 88% 96% 
Azithromycin (API)  
 
2% 2% 2% 2% 2% 
Urea   10%    
Propylen Glycol  
 
  10%   
IPM     10%  
Oleic acid      2% 
 
 
 
 
 
 46 
 
 
2.3.4 – Manufacturing procedure: 
1- Add 30 g ethyl alcohol to a mixing vessel. 
2- Add 33.89 g purified water to the mixing vessel, and mix well. 
3- Dissolve Methyl paraben, Propyl paraben in the alcoholic solution and mix well  
     for 2 minutes. 
4- Add cremophore RH40 to the mixing vessel and mix for 3 minutes. 
5- Add Azithromycin to the above solution and mix for 5 minutes. make sure of    
     complete dissolution of Azithromycin powder.  
6- Add the PE and mix well for 3 minutes.  
7- Add sepigel slowly with continuous mixing till a gel structure is formed.  
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2.4- Permeability test methodology:  
1- Preparation of the synthetic membrane: 
The synthetic membrane is composed of three layers; polyamide filter 
membrane inserted between two layers of dialysis membrane. The two layers of 
dialysis membrane were soaked for half an hour in distilled water for hydration 
before use. The polyamide filter membrane was soaked in octanol for 24 hours to 
simulate the lipophilic barrier in the skin and captured between the dialysis 
membrane to prevent octanol from floating or leaving the filter membrane during 
the diffusion experiments (13). 
This design of the synthetic membrane was proved to be useful in a previous study 
performed by Mr. Al-Hindi in the University of Jordan in his thesis about 
Diclofenac complexes with some metals as candidate system for drug delivery in 
the year 2002, the correlation between diffusion through the SC and the synthetic 
membrane was detected (34).  
2- Receptor and donor phase: 
A 30% hydro alcoholic medium is used as the receptor phase in our skin 
permeation studies based on the fact that Azithromycin (API) is freely soluble in 
this medium. 
The receptor solution was thoroughly degassed to prevent the formation of bubbles 
beneath the synthetic membrane, and samples were withdrawn at specified time 
intervals.  
Thus plots could be generated showing the amount of drug released versus 
time. Most often the receptor solvent is present in a volume that allows sink 
conditions to be approximated throughout the course of the experiment.  
In all instances, the thermodynamic activity of the drug in the receptor fluid should 
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not exceed 10 %of its thermodynamic activity in the donor medium to 
maintain a favorable driving force for permeation and to assure reasonable 
and efficient collection of diffusant.  
 
Diffusion test parameters: 
 
Sample weight :                                1.8 gm 2% Azithromycin gel. 
 
Sample content of Azithromycin:     36 mg. 
 
Total diffusion area available:          3 cm
2
 
 
Temperature controlled at:                32-34C 
  
Total diffusion time:                         6 hours. 
 
Total volume of MFD cell:               20.6 ml. 
 
Total membrane height:                    0.016 cm. 
 
Sample size:                                     1.0 ml 
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2.5- Calculation methods:  
1- From the biological assay procedure, we can measure the concentration of 
Azithromycin in the 1 ml sample taken during the diffusion test by 
measuring the diameter of the inhibition zones for the different 
concentrations prepared and by using certain pharmacopeial equations to 
convert the diameter into concentration, the equations available in  part 2.7.  
 
2- According to the table no. 12 
Sampling 
time  
 Sample 
conc.mg/ml 
Qc  
mg/20.6 ml 
Qa 
(mg) 
M 
(mg/cm
2
) 
J 
(mg/cm2/hour) % diffused 
 
-Qc is the current quantity of the drug diffused at any time which equals to the 
sample concentration of the drug at that time multiplied by the volume of the 
receiver solution (20.6ml).  
-Qa is the accumulative quantity diffused equals to the total quantity diffused at 
certain time plus the quantity removed during all last sampling. 
Example:  
The accumulative quantity after 4 hours of diffusion equals to the concentration 
of drug (mg/ml)at time 4 hours *20.6 ml+mg/1 ml sample at 3 hours+ mg/1 ml 
sample at 2 hours+ mg/1 ml sample at 1 hours+ mg/1 ml sample at 0.5 hours. 
- M equals to the accumulative amount diffused divided by area of the 
synthetic membrane (3cm
2
). 
- J represent the accumulative amount diffused divided by area of the synthetic 
membrane (3cm
2
) divided by time. 
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- % diffused equals to the amount of drug diffused divided by the total 
available amount in the donor compartment (36 mg).    
3- According to the figure 16, we can plot time versus M, and then we 
determine the steady state area and plot again the steady state area versus 
time. 
- By chart options on the excel software, one can choose equation and R2 to 
determine the intercept and the slope of the steady state area. 
4- According to the table no.13   
Formula       Slope               Intercept             
TL =intercept 
/slope     D=h
2
/6 TL         
P = slope / 
concentration K=P.h/D           
 
- Lag time is calculated by dividing the intercept / the slope.( hr) 
- Diffusion coefficient (D) = h2/6 TL  (cm2 / hr)        
- The permeability (p) = slope / concentration in the donor compartment.                        
P = ( cm / hr )  
- The partition coefficient (K) = Ph/D 
- The Enhancement ratio (ER) = P after the addition of PE / P before the 
addition of PE. 
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2.6- Chemical assay of Azithromycin as the USP28  
"Note : Use water that has a resistivity of not less than 18 Mohm/cm.  
Mobile phase:  
Dissolve 5.8 g of monobasic potassium phosphate in 130 mL of water, add 870 mL 
of acetonitrile, and mix. Adjust with about 6 mL of 10 N potassium hydroxide to a 
pH of 11.0 ± 0.1, and pass through a filter having a 0.5-µm or finer porosity, and 
degas, make adjustments if necessary.  
Standard stock preparation:  
Transfer about 16.5 mg of USP Azithromycin RS, accurately weighed, to a 100-
mL volumetric flask, add 10 mL of acetonitrile, and dissolve by swirling and with 
the aid of brief sonication. Dilute with acetonitrile to volume, and mix.  
Standard preparation: 
Transfer 2.0 mL of the Standard stock preparation to a 100-mL volumetric flask, 
dilute with Mobile phase to volume, and mix to obtain a Standard preparation 
having a known concentration of about 0.0033 mg of USP Azithromycin RS per 
mL.  
Assay preparation: 
 Transfer about 16.5 mg of Azithromycin, accurately weighed, to a 100-mL 
volumetric flask, add 10 mL of acetonitrile, and dissolve by swirling and with the 
aid of brief sonication. Dilute with acetonitrile to volume, and mix. Transfer 2.0 
mL of the solution so obtained to a 100-mL volumetric flask, dilute with Mobile 
phase to volume, and mix.  
Chromatographic system: 
The liquid chromatograph is equipped with an amperometric electrochemical 
detector with dual glassy carbon electrodes operated in the oxidative screen mode 
with electrode 1 set at +0.70 ± 0.05 V and electrode 2 set at +0.82 ± 0.05 V, and 
the background current optimized to 85 ± 15 nanoamperes, a 4.6-mm × 5-cm guard 
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column that contains 5-µm packing L29 and a 4.6-mm × 15-cm analytical column 
that contains 5-µm packing L29 or 3-µm packing L49 without the guard column. 
The flow rate is about 1.5 mL per minute. Chromatograph the Resolution solution, 
and record the responses as directed for Procedure: the relative retention times are 
about 0.7 for azaerythromycin A and 1.0 for Azithromycin  with the L29 column 
and about 0.8 for azaerythromycin A and 1.0 for Azithromycin with the L49 
column; and the resolution, R, between azaerythromycin A and Azithromycin is 
not less than 2.5. Chromatograph the Standard preparation, and record the 
responses as directed for procedure. 
 The tailing factor for the Azithromycin  peak is not less than 0.9 and not more 
than 1.5; the column efficiency is not less than 1000 theoretical plates; and the 
relative standard deviation for replicate injections is not more than 2.0%.  
Procedure:  
 Separately inject equal volumes (about 50 µL) of the Standard preparation and the 
Assay preparation into the chromatograph, record the chromatograms, and measure 
the areas for the major peaks. Calculate the quantity, in µg, of Azithromycin 
(C38H72N2O12 ) in each mg of Azithromycin taken by the formula: 
  
(WP/w)( r U / r S ), 
in which W is the quantity, in mg, of USP Azithromycin  RS taken to prepare the 
Standard preparation; P is the potency, in µg of  Azithromycin  per mg, of USP 
Azithromycin RS; w is the quantity, in mg, of Azithromycin taken to prepare the 
Assay preparation; and r U and r S are the Azithromycin peak responses obtained 
from the Assay preparation and the Standard preparation, respectively." (32)  
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2.7- Biological assay of Azithromycin  
Procedure:  
1. Preparation of Standard Stock Solution 
     1.1 Dissolve 20-100 mg quantity of USP Reference Standard (working Standard of     
        the tested antibiotic (accurately weighed) to prepare a stock solution in a certain    
         concentration (Table 1 – USP28).   
1.2. Make a proper dilutions in a solvent specified, to obtain the target concentrations   
       Dilute to the required concentration. 
1.3. Store in a refrigerator (where applicable) and use within the period indicated       
according to the validation method recommendations for each antibiotic     
 
2. on the day of assay: using the stock solution, 
2.1 Prepare from the standard stock solution, three standard target concentrations 
Standard low       = lowest concentration  
Standard Median = median concentration  
Standard High     = highest concentration  
Note: Dose ratio between the two adjacent doses is 1.25   
       3. Preparation of Sample 
                        3.1. Assign to the unknown sample an assumed potency per unit weight or   
                               volume, depending on the declared potency by the manufacturer.             
3.2. On this assumption, prepare on the day of assay: A stock solution and a test  
solutions as specified for each antibiotic using the same final diluent as used for  
standard.   
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         3.3. From a sample stock solution, prepare three test sample target concentrations as 
                 well as standard concentrations: 
Test low       = lowest concentration  
Test median = median concentration  
Test high     = highest concentration 
Note: Dose ratio between the two adjacent doses is 1.25   
      4. Microorganisms and inoculum: 
          4.1 Test Organism: 
            The test organism is Micrococus Luteus ATCC # 9341 
4.2. Preparation of the Inoculum’s: 
4.2.1. Take 1 loopful of frozen culture (at – 80 °C) and transfer to 2 ml SCDM 
          or BHIM. , mix gently on vortex     
4.2.2. Pipette 1 ml from the SCDM or BHIM and inoculate on SCDA or     
           BHIA plate or one loopful from slant culture and streak on SCDA or    
           BHIA plate.  
       4.2.3. Remove the growth from a recently grown slant or culture of the                   
               organism with 3 mL of sterile saline TS and sterile glass beads. 
  
         4.2.4. Inoculate by streaking on a surface of BHIA or SCDA agar medium specified           
                for this microorganism.    
        4.2.5. Incubate at 35 C+2 for the time indicated (18-24 hour).  
        4.2.6. At the end of incubation, prepare the stock suspension by collecting the surface  
                growth in 50 ml of sterile saline TS. 
        4.2.7. Measure the Transmittance % (T) of the bacterial suspension using visible             
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                 Spectrophotometer at wavelength = 140 nm. The transmittance of the suspension   
            shall be around 23%-27%  
       4.2.8. Add a portion of bacterial stock suspension to a sufficient amount of agar    
                  medium melted and cooled to 45
o
 - 50
 o
 C and swirl to homogenize.  
         5.  Calculation of potency estimate by three dose level 
             To calculate the potency of antibiotic from the data obtained by the cylinder  
             plate method, using the following equations provided by USP 
          5.1. E = The difference in response between adjacent dose levels  
             E = ¼ (S3+T3) – (S1+T1) 
           5.2. F= The difference in response between the two preparations                               
                                 (Standard and sample) 
                  F= ⅓ (T3 + T2 + T1) – (S3 + S2 + S1)   
           5.3.   I= Log ratio of the doses (log ratio between two adjacent doses). 
                            I= Log dilution factor. 
           5.4.   b= the slope of response  
                            b= E/I 
           5.5. M = the log of the potency ratio 
                            M=F/b 
            5. 6. Potency ratio = Anti log10 M X 100 %. 
                             * Potency ratio = antilog10 MX100% 
     S1 = Standard low concentration              T1 = Sample low concentration          
     S2 = Standard medium concentration       T2 = Sample medium concentration  
     S3 = Standard high concentration             T3 = Sample high concentration 
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Results and discussion 
3.1- Assay method: 
This product can be analyzed chemically or biologically, but we managed to 
determine the potency of the product biologically where potency can be 
determined by measuring the diameter of inhibition on the culture plate for 
organism Micrococus luteus ATCC #9341.    
 
 
Figure 17: sample of the biological assay plates where the zone of inhibition is 
calculated and compared to standard plate using Micrococus luteus ATCC #9341 
organism as our reference.   
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3.2- In the first object of this study, it was found that Azithromycin is soluble in 
30% ethanol/water, a 2% azithromycin in 30% ethanol/water solution maintained 
stable at room temperature for up to 6 months but at 37°C there was some decay 
(16%) at 26 weeks. The stability was greatest at pH 6.8 and was unaffected by 
ambient light exposure, this result was assured by a previous study done by RC 
McHugh 
A1
, A Rice 
A1
, ND Sangha 
A1
, MA McCarty 
A1
, R Utterback 
A1
, JM 
Rohrback 
A1
, BE Osborne 
A1
, AB Fleischer Jr 
A1
, SR Feldman 
 
in the Department 
of Dermatology Wake Forest School of Medicine Winston-Salem North Carolina 
USA.(?) 
3.3- In the second part of this study, a stable gel structure was prepared according 
to formula B which consist of :  
Table 6: Gel formula B  
Material name  Function  Concentration  
Azithromycin    API 2% 
Purified water    Solvent 33.89% 
Ethyl alcohol    Solvent 30% 
Cremophore RH40    Solubilizer 1% 
Sepigel (Polyacrylamide and C13-14 
Isoparaffin and Laureth-7) 
  Gelling agent 3% 
Methyl paraben    preservative  0.1% 
Propyl paraben    Preservative    0.01% 
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The 2% Azithromycin gel structure obtained by gel base Formula B without 
adding any penetration enhancer achieves all the predetermined specifications 
which are:  
Table 7 : Specification data for 2% Azithromycin in Formula B. 
Specification  Limit Result Verification method   
Color Transparent Transparent   visual test 
pH 9.0 – 10.5  9.9 pH meter 
Viscosity at 23C 3000-3500 cps   3400 cps               Brookfield viscometer 
Crystals None None   Microscopically exam.  
Irritation None None  Human skin application 
Compatibility Compatible   Compatible Chemical assay   
  
The in-use stability of the 2% Azithromycin gel was detected for 2 months where 
the  active ingredient was mixed directly with the gel media before use where the 
Azithromycin dose shall be provided unmixed in a hard gelatin capsule and the 
normal period of treatment is mainly 7 days.  
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3.4-The third part of this study includes the introduction of different penetration 
enhancers into the 2% Azithromycin gel structure to prepare different formulations 
where 2 studies have been run on these formulations: 
3.4.1- A 2 months shelf life stability study, to investigate most of the chemical and 
physical characteristics of the preparations as presented in the tables below:  
Storage conditions: at room temperature.  
Packaging material: polyethylene well closed gar. 
1-Formula 2: Penetration enhancer 10% Urea 
 
Table 8: Specification data for Formula 2 with 10% urea. 
                                                              0 Month         Month 1         Month 2          
Specification  
 Limit Result Result Result 
Color Transparent Transparent   Transparent Transparent 
pH 9.0 – 10.5 9.7 9.5 9.3 
Viscosity at 23C 3000-3500 cps    3250 cps               3000 cps 3000 cps 
Crystals None None  
None  None  
Irritation None None  
None  None  
Compatibility Compatible   Comply  Comply Comply 
Assay of 
Azithromycin  95-105% 98% 97% 97% 
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2- Formula 3: Penetration enhancer 10% Propylene glycol 
Table 9 : Specification data for Formula 3with 10% propylene glycol. 
                                                              0 Month         Month 1         Month 2          
Specification  
 Limit Result Result Result 
Color Transparent Transparent    Transparent  Transparent 
pH 9.0 – 10.5  10.3 9.8 9.8 
Viscosity at 23C 3000-3500 cps    3500 cps               3200 cps  3200 cps  
Crystals None None  
None  None  
Irritation None None  
None  None  
Compatibility Compatible   comply comply comply 
Assay of 
Azithromycin  95-105% 101% 97% 97% 
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3 – Formula 4: Penetration enhancer 10% IPM 
Table 10 : Specification data for Formula 4 with 10% IPM. 
                                                               0 Month      Month 1         Month 2          
Specification 
  Limit Result Result Result 
Color White  White   White   White  
pH 9.0 – 10.5  10.1 9.7 9.7 
Viscosity at 23C 3000-3500 cps    3270 cps               3000 cps  3000 cps  
Crystals None None  None  None  
Irritation None None  None  None  
Compatibility Compatible   comply comply comply 
Assay of 
Azithromycin  
95-105% 100.5% 97% 97% 
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4-Formula 5: Penetration enhancer 2% Oleic acid  
  Table 11 : Specification data for Formula 5 with 2% oleic acid. 
                                                               0 Month      Month 1       Month 2          
Specification  
 Limit Result Result Result 
Color White White   White White 
pH 9.0- 10.5  8.7  8.19 8.19 
Viscosity at 23C 3000-3500 cps   2700 cps  2500 cps  2500 cps  
Crystals None None None None 
Irritation None None None None 
Compatibility Compatible   comply comply comply 
Assay of 
Azithromycin  
95-105% 97% 97% 96% 
 
* pH and viscosity fail to achieve specification.  
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3.4.2 - A diffusion study has been done to the different preparations using MFDC 
for each penetration enhancer according to the predetermined conditions in point  
no.2.4 and the results were found as follows: 
1- Formula No. 1:                          2% Azithromycin gel without PE 
 
Table 12: Data obtained by the diffusion of 2% Azithromycin gel formula 1 
through a synthetic membrane in a Modified Franz diffusion cell in the absence of 
penetration enhancer. 
 
Sampling 
time  
Diameter 
mm 
Sample 
conc. 
mg/ml 
Qc 
mg/20.6 ml 
Qa 
(mg) 
M 
(mg/cm2) 
J 
(mg/cm2/hour) 
% 
diffused 
0 0.00 0.0000 0.000 0.000 0.000 0.000 0 
0.5 15.66 0.0480 0.989 0.989 0.330 0.627 3% 
1 14.47 0.0740 1.524 1.132 0.524 0.524 4% 
2 14.39 0.1280 2.637 2.727 0.920 0.430 8% 
3 15.23 0.2220 4.133 4.823 1.308 0.536 13% 
4 16.33 0.2750 5.665 6.137 2.046 0.511 17% 
5 17.10 0.3050 6.283 7.030 2.343 0.469 20% 
6 17.38 0.3100 6.386 7.438 2.479 0.413 21% 
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Figure 18: In vitro permeation profile for the cumulative amount of Azithromycin 
penetrated per unit area of synthetic membrane (mg/cm2) in formula no. 1 as a 
function of time (hr) in the absence of Penetration enhancer.  
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Figure 19: In vitro Steady state permeation profile for the cumulative amount of 
Azithromycin penetrated per unit area of synthetic membrane (mg/cm2) in 
formula no.1 as a function of time (hr) in the absence of Penetration enhancer. 
 
Diffusion results:  
Table 13: Diffusion results for formula 1 obtained by MFDC study. 
 
 Formula       Slope               Intercept             
TL=intercept 
/slope     D=h2/6TL         
P = slope / 
concentration  K=P.h/D           
1 0.2912 0.8084 2.77 1.45E-05 0.0146 15.16 
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2- With 10% Urea 
Formula No. 2:                                 2% Azithromycin gel with 10% Urea 
 
Table 14 : Data obtained by the diffusion of 2% Azithromycin gel formula no 2 
through a synthetic membrane in a Modified Franz diffusion cell in the presence 
of 10% Urea as penetration enhancer.  
Sample 
time  
Diameter 
mm 
Sample 
conc.  
mg/ml 
Qc 
mg/20.6 ml 
Qa 
(mg) 
M 
(mg/cm2) 
J 
(mg/cm2/hour) 
% 
diffused 
0 0 0.0000 0.000 0.000 0.000 0.000 0% 
0.5 15.63 0.1800 3.708 3.708 1.236 2.472 10% 
1 18.70 0.6320 13.019 13.199 4.400 4.400 37% 
2 18.96 0.7000 14.420 15.232 5.077 2.539 42% 
3 19.03 0.8000 16.480 17.992 5.997 1.999 50% 
4 19.00 0.8000 16.480 18.792 6.264 1.386 52% 
5 20.33 1.0000 20.300 23.712 7.904 1.141 66% 
6 20.47 1.0500 21.630 25.742 8.141 1.430 72% 
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Figure 20: In vitro permeation profile for the cumulative amount of Azithromycin 
penetrated per unit area of synthetic membrane (mg/cm2) in formula no.2 as a 
function of time (hr) in the presence of 10% Urea as Penetration enhancer.  
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Figure 21: In vitro Steady state permeation profile for the cumulative amount of 
Azithromycin penetrated per unit area of synthetic membrane (mg/cm2) in 
formula no.2 as a function of time (hr) in the presence of 10% Urea as penetration 
enhancer.  
Diffusion parameters:  
Table15: Diffusion parameters for formula 2 obtained by MFDC study. 
 
Formula       Slope               Intercept             
TL =intercept 
/slope     D=h2/6 TL         
P = slope / 
concentration K=P.h/D           
2 0.939 2.932 3.15 1.35E-05 0.047 39.52 
Enhancement ratio for 10% Urea =0.047 / 0.0146 = 3.22 
Urea is among the amide compounds and is widely used in amounts of around         
5-10% in moisturizing creams and topical steroids (??).  
Urea is a hygroscopic compound, which hydrates the stratum corneum and hence 
improves permeation of drug molecules. By increasing the amount of water present 
within stratum corneum, this layer swells and even though the passageway of drug 
molecules gets longer but nevertheless because of the decompression of cells and an 
increase in the rate of passage of drug molecules, the extent of drug permeation 
increases 
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3- with 10% propylene glycol  
Formula No. 3:                                 2% Azithromycin gel with 10% PG 
  
Table 16 : Data obtained by the diffusion of 2% Azithromycin gel formula no 3 
through a synthetic membrane in a Modified  Franz diffusion cell  in the presence 
of 10% propylene glycol as penetration enhancer.  
 
Sample 
time  
Diameter 
mm 
Sample 
conc. 
mg/ml 
Qc 
mg/20.6 ml 
Qa 
(mg) 
M 
(mg/cm2) 
J 
(mg/cm2/hour) 
% 
diffused 
0 0 0.0000 0.000 0.000 0.000 0.000 0 
0.5 17.65 0.3140 6.468 6.468 2.138 4.312 18% 
1 17.67 0.3130 6.510 6.824 2.275 2.275 19% 
2 19.33 0.3000 12.330 12.990 4.330 2.165 36% 
3 19.27 0.6720 13.843 15.073 5.024 1.675 42% 
4 19.39 0.7430 15.368 17.270 5.713 1.439 48% 
5 19.14 0.7270 15.635 18.283 6.094 1.219 51% 
6 19.32 0.7630 15.718 19.125 6.375 1.062 53% 
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Figure 22: In vitro permeation profile for the cumulative amount of Azithromycin 
penetrated per unit area of synthetic membrane (mg/cm2) in formula no. 3 as a 
function of time (hr) in the presence of 10% Propylene glycol as a penetration 
enhancer.  
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Figure 23: In vitro Steady state permeation profile for the cumulative amount of 
Azithromycin penetrated per unit area of synthetic membrane (mg/cm2) in 
formula no. 3 as a function of time (hr) in the presence of 10% Propylene glycol as 
a Penetration enhancer.  
 
Diffusion parameters:  
Table 17 : Diffusion parameters for formula 3 obtained by MFDC study.  
Formula       Slope               Intercept             
TL =intercept 
/slope     D=h2/6 TL         
P = slope / 
concentration K=P.h/D           
3 0.439 3.8373 8.74 4.88E-06 0.022 71.95 
 
 
Enhancement ratio for 10% Propylene glycol =0.022 / 0.0146 = 1.51  
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4-With 10% IPM 
Formula No. 4:                                 2% Azithromycin gel with 10% IPM 
  
Table 18 : Data obtained by the diffusion of 2% Azithromycin gel formula no 4 
through a synthetic membrane in a Modified Franz diffusion cell in the presence 
of 10% IPM as penetration enhancer.  
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Figure 24: In vitro permeation profile for the cumulative amount of Azithromycin 
penetrated per unit area of synthetic membrane (mg/cm2) in formula no. 4 as a 
function of time (hr) in the presence of 10% IPM as a Penetration enhancer.  
 
Sample   
time  
 
Diameter 
mm 
Sample 
conc. 
mg/ml 
Qc 
mg/20.6 ml 
Qa 
(mg) 
M 
(mg/cm2) 
 
J 
(mg/cm2/hour) 
% 
diffused 
0 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
0.5 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
1 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
2 0.5 0.0012 0.025 0.025 0.008 0.004 0% 
3 0.5 0.0012 0.025 0.026 0.009 0.003 0% 
4 0.5 0.0012 0.025 0.027 0.009 0.002 0% 
5 0.5 0.0012 0.025 0.028 0.009 0.002 0% 
6 0.5 0.0012 0.025 0.030 0.010 0.002 0% 
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Figure 25: In vitro Steady state permeation profile for the cumulative amount of 
Azithromycin penetrated per unit area of synthetic membrane (mg/cm2) in 
formula no. 4 as a function of time (hr) in the presence of 10% IPM as a 
penetration enhancer.  
                                             
Diffusion parameters: 
Table 19: Diffusion parameters for formula 4 obtained by MFDC study 
Formula       Slope               Intercept             
TL =intercept 
/slope     D=h2/6 TL         
P = slope / 
concentration K=P.h/D           
4 0.0004 0.007 17.5 2.44E-06 0.00002 0.14 
 
Enhancement ratio for 10% IPM =0.00002 / 0.01438 = 0.001 
 
IPM is an aliphatic ester, it penetrates between the lipid bilayers of stratum 
corneum and due to its' chain structure, disrupts the order and arrangement of lipid 
bilayers of stratum corneum and hence improves drug permeation into this layer. 
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5-With 2 % Oleic acid  
Formula No. 5:                                 2%Azithromycin gel with 2% Oleic acid  
 
 
Table 20 : Data obtained by the diffusion of 2% Azithromycin gel formula no 5, 
through a synthetic membrane in a Modified Franz diffusion cell, in the presence 
of 2% Oleic acid as penetration enhancer.  
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Figure 26: In vitro permeation profile for the cumulative amount of Azithromycin 
penetrated per unit area of synthetic membrane (mg/cm2) in formula no.5 as a 
function of time (hr) in the presence of 2 % Oleic acid  as a Penetration enhancer.  
Sample 
time  
 
Diameter 
mm 
Sample 
conc. 
mg/ml 
Qc 
mg/20.6 ml 
Qa 
(mg) 
M 
(mg/cm2) 
J 
 
(mg/cm2/hour) 
% 
diffused 
0 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
0.5 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
1 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
2 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
3 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
4 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
5 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
6 0.0 0.0000 0.000 0.000 0.000 0.000 0% 
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Figure 27: In vitro Steady state permeation profile for the cumulative amount of 
Azithromycin penetrated per unit area of synthetic membrane (mg/cm2) in 
formula no.5 as a function of time (hr) in the presence of 2% Oleic acid as a 
Penetration enhancer.  
Diffusion parameters: 
Table 21: Diffusion parameters for formula 5 obtained by MFDC study.  
 
Formula       Slope               Intercept             
TL =intercept 
/slope     D=h2/6 TL         
P = slope / 
concentration K=P.h/D           
5 0 0 0 0 0 0 
Enhancement ratio for 2 % Oleic acid =0.0000 / 0.01438 = 0 
The effect of oleic acid in amount of 2% on the permeability of Azithromycin is 
shown in table 22 and the calculated permeability equal to zero. 
Even oleic acid is a popular penetration enhancer and penetrates into the stratum 
corneum and decompresses this layer and hence reduces its' resistance to drug 
penetration, it can also accumulate within the lipid bilayers of stratum corneum cells 
and hence increase their flowability and penetration ability, but in high 
concentrations like used in this study (2%), oleic acid inhibit permeability to zero. 
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The reason for this inhibition is may be due to the formation of oleic acid layer on 
the membrane because of its low solubility in the aqueous domain and consequently 
increases the diffusion coefficient.  
 
3.5- Selection of the best penetration enhancer  
By determining all diffusion parameters for the different penetration enhancers 
from the above experiments as the table below, we can make certain comparison 
such as table 22 and 23: 
 
Table 22: Diffusion parameters for the different penetration enhancers 
Penetration 
enhancer Slope Intercept 
TL              
( hr) 
D              
( cm
2
/hr) 
P                
( cm /hr ) K 
Enhance
ment ratio 
( ER)  
Without 
penetration 
enhancer  0.2912 0.8084 2.77 1.45E-05 0.0146 15.16 1 
Urea  0.939 2.932 3.15 1.35E-05 0.047 39.52 3.22 
Propylene 
glycol 0.439 3.8373 8.74 4.88E-06 0.022 71.95 
 
1.51 
IPM 0.0004 0.007 17.5 2.44E-06 0.00002 0.14 
0.001 
Oleic acid  0 0 0 0 0 0 
0 
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By plotting Time versus M for each penetration enhancer  
Table 23: Time v s M for all penetration enhancers 
Time 
(hr) Without  Urea 
Propylene 
glycol IPM 
Oleic 
acid 
0 0 0 0 0 0 
0.5 0.33 1.236 2.138 0 0 
1 0.524 4.4 2.275 0 0 
2 0.92 5.077 4.33 0.008 0 
3 1.308 5.997 5.024 0.009 0 
4 2.046 6.264 5.713 0.009 0 
5 2.343 7.904 6.094 0.009 0 
6 2.479 8.141 6.375 0.01 0 
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Figure 28:  Plot of Time versus M for all penetration enhancers   
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Enhancement ratio for each penetration enhancer can be plotted as figure 29 for 
comparison such as:  
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Figure 29: Enhancement ratio for each penetration enhancer  
Lag time (TL) for each penetration enhancer can be plotted as shown in figure 30 
for comparison such as:     
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Figure 30:  A plot of TL of different penetration enhancers  
 77 
 
Diffusion coefficient (D) for each penetration enhancer can be plotted in Figure 
31for comparison such.  
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Figure 31: A plot of diffusion coefficient of different penetration enhancer 
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Conclusion    
Results show that among the penetration enhancers used, the use of urea at a 
concentration of 10% w/w had the greatest effect on the permeability rate of 
Azithromycin, and produce the highest enhancement ratio among all the 
penetration enhancers examined, followed by propylene glycol 10%. 
 The other penetration enhancers used like oleic acid 2% and IPM 10% were 
found to have an inhibitory effect on the permeability rate of Azithromycin 
through the synthetic membrane.  
 The results of this study on Azithromycin shows that penetration enhancers like 
IPM and Oleic acid whom work to increase the fluidity of the lipid domain always 
decrease or inhibit the permeability of the drug, while other penetration enhancers 
like Urea and Propylene glycol whom work to increase the fluidity of the aqueous 
domain always increase the permeability of the drug.   
UR is a hygroscopic compound, which hydrates the stratum corneum and hence 
improves permeation of drug molecules. By increasing the amount of water present 
within stratum corneum, this layer swells and even though the passageway of drug 
molecules gets longer but nevertheless because of the decompression of cells and an 
increase in the rate of passage of drug molecules, the extent of drug permeation 
increases 
The rate of permeability enhancement was found to be as follow  
Urea > Propylene glycol > without penetration enhancer > IPM > Oleic acid  
The lag time TL was found on the opposite order  
Oleic acid > IPM > Propylene glycol > Urea  
This finding suggests that the type and concentration of a penetration enhancer for 
incorporation into a specific formulation containing a particular drug should be 
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selected carefully and following extensive initial studies, in order to achieve a 
formulation with desirable drug permeability rate and efficacy. 
Further work shall be done on this product in future if a topical form of               
Azithromycin to investigate the effect of different concentrations of different 
penetration enhancers.  
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الملخص 
 
 
إٌ رحقٛق الايزظبص انكبيم نلأدٔٚخ انزٙ رقذو عهٗ شكم يغزحؼشاد نهًغح انخبسخٙ عهٗ اندهذ أطجح 
  .يٍ أْى الأيٕس انزٙ ٚزى دساعزٓب فٙ يدبل انًغزحؼشاد اندهذٚخ
إٌ ْذف ْزِ انذساعخ ْٕ رحؼٛش يغزحؼش نلاعزعًبل انًٕػعٙ عهٗ اندهذ نًبدح انًؼبد انحٕٛ٘ 
 ٔنلاعزعًبل ثشكم يجبشش فٙ علاج انًشع اندهذ٘ انًغًٗ حت انشجبة NICYMORHTIZA
   ENCA MUIRETCABINOIPORP يٍ ثكزٛشٚب يغًبح ٔانًزغجت SIRAGLUV ENCA
ٔرنك نهزغهت عهٗ يشكهخ انًُبعخ أٔ انحظبَخ انزٙ ٚكَٕٓب انًٛكشٔة ػذ الأدٔٚخ انزقهٛذٚخ انًغزعًهخ نعلاج 
 .انًشعْزا 
 انعلاج فعبلا ًٔيقجٕلا ًْٙ احذ أْى ل انزٙ رحقق خًٛع انًزطهجبد انًٕػٕعخ ندعأنظٛغخ انًُبعجخإٌ رطٕٚش 
  .انذساعخأْذاف 
 فٙ رشكٛجخ  أٔ انُفبرٚخردبسة يخزهفخ رى عًهٓب نكٙ َقٛى رأثٛش إدخبل ثعغ انًٕاد انًحغُخ نلايزظبص
  عهٗ شكم خم نلاعزعًبل انًٕػعٙ اندهذ٘ ٔرنك ثقٛبط َفبرٚخ انذٔاء يٍ NICYMORHTIZA%2
 .خلال غشبء َفبر طُبعٙ ٚشبثّ فٙ رشكٛجزّ اندهذ اٜديٙ  
 ٌانجش ٔثهٙ يثم انٕٛسٚب،  أٔ انُفبرٚخفٙ ْزِ انذساعخ، رى اعزعًبل إَٔاع يخزهفخ يٍ يحغُبد الايزظبص
  .خلاٚكٕل، اٚضٔثشٔثم يٛشعزبد ٔحبيغ الأٔنٛٛك
يحهٕل اٚثٛم % 03 انُفبرٚخ حٛث رى اعزعًبل نفحضLLEC ZNARF رى اعزعًبل خهٛخ يحغُخ يٍ خلاٚب 
 .رقشٚجبً  يئٕٚخ 23انكحٕل ٔانًبء فٙ انٕعؾ انًغزقجم فٙ انخهٛخ عهٗ دسخخ حشاسح 
رى عحت انعُٛبد يٍ انٕعؾ انًغزقجم عهٗ فزشاد يخزهفخ خلال انذساعخ ٔقذ رى حغبة كًٛخ انًبدح 
 انًزٕاخذح فٙ انعُٛخ ٔانزٙ َفزد يٍ خلال انغشبء انُفبر حٛث رى اعزًبد ؽشٚقخ NICYM0ORHTIZA
 .يعُٛخ نذساعخ انزشكٛض ثبعزخذاو انفحض انجٕٛنٕخٙ
نٓب اكجش % 01نقذ أظٓشد انُزبئح ثبٌ يٍ ثٍٛ انًٕاد انًحغُخ نلايزظبص فقذ ٔخذ أٌ يبدح انٕٛسٚب ثزشكٛض 
رأثٛش عهٗ عًهٛخ َفبرٚخ انذٔاء عجش انغشبء انُفبر ٔرحقق أعهٗ َغجخ رخغٍٛ نهُفبرٚخ ثى رلاْب فٙ انزشرٛت 
  %.01 خلاٚكٕل ثزشكٛض ٌانجش ٔثهٙحغت انزأثٛش الأكجش يبدح 
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إٌ انًٕاد الأخشٖ انًحغُخ نهُفبرٚخ انزٙ اعزعًهذ فٙ انذساعخ يثم حبيغ الأٔنٛٛك أٔ اٚضٔثشٔثم - 
  حٛث قبيذ ثإحجبؽ  NICYMORHTIZAيٛشعزبد فقذ ٔخذد راد رأثٛش عهجٙ عهٗ انُفبرٚخ نذٔاء 
. انُفبرٚخ إنٗ حذٔد رظم إنٗ انظفش
فٙ يحبٔنخ نزفغٛش انُزبئح انزٙ حظهُب عهٛٓب فٙ انذساعخ ٔثًعشفزُب انًغجقخ ثٓزِ انًٕاد ٔثكٛفٛخ عًهٓب يًكٍ 
  .أٌ َظم إنٗ الاعزُزبج انزبنٙ
إٌ انًٕاد انزٙ رحغٍ الايزظبص عٍ ؽشٚق عًهٓب عهٗ صٚبدح انغٕٛنخ ٔالاَذفبع فٙ انٕعؾ انًبئٙ داخم 
   ثًُٛب انًٕاد انزٙ ٚكٌٕ عًهٓب عهٗ انٕعؾ NICYMORHTIZAخلاٚب اندهذ رحغٍ يٍ َفبرٚخ يبدح 
. يٍ انًغزحؼشاد انحبٔٚخ نٓزِ انًٕاد NICYMORHTIZAؽ َفبرٚخ يبدح ةانضٚزٙ فأَٓب رح
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إقرار  
 
 
 
اقش أَب يقذو انشعبنخ أَٓب قذيذ ندبيعخ انقذط نُٛم دسخخ انًبخغزٛش ٔ أَٓب َزٛدخ أثحبثٙ 
انخبطخ ثبعزثُبء يب رى الإشبسح نّ حٛثًب ٔسد، ٔ أٌ ْزِ انشعبنخ أٔ أ٘ خضء يُٓب نى ٚقذو نُٛم أٚخ 
. دسخخ عهٛب لأ٘ خبيعخ أٔ يعٓذ
 
 
 
 
 
                      
    ٔنٛذ ٕٚعف كبيم 
                             
: ............................. انزبسٚخ: ......................                                       انزٕقٛع
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ثشَبيح انذساعبد انعهٛب فٙ انزكُٕنٕخٛب انزطجٛقٛخ ٔ انظُبعٛخ 
 
 
عًبدح انذساعبد انعهٛب 
 
 
 
تحضٍر المضاد الحٍوي أزثروماٌسٍن على شكل جل موضعً لاستخذامه فً علاج حة 
الشثاب و فحص تأثٍر تعض المواد المحسنة للنفارٌة على درجة نفارٌة المضاد الحٍوي 
 
 
 
ٔنٛذ ٕٚعف كبيم :        اعى انطبنت
 
               7340199:     انشقى اندبيعٙ
 
 
 
انذكزٕس إثشاْٛى أنكٛبنٙ : انًششف 
 
 
 
 6002/1/32: َٕقشذ ْزِ انشعبنخ ثزبسٚخ
 
ندُخ انًُبقشخ انًذسخخ أعًبئٓى ٔ رٕقٛعٓى 
 
....................... رٕقٛع .......................  يششف سئٛظ/ سئٛظ انهدُخ / انذكزٕس إثشاْٛى أنكٛبنٙ - 1
  
...................... رٕقٛع /                 ........................  يًزحٍ داخهٙ / انذكزٕس ٔدٚع عهطبٌ  - 2
 . 
....................... رٕقٛع /                  .......................  يًزحٍ خبسخٙ/ انذكزٕس َعًبٌ يبنكٛخ - 3
 
 
 
خبيعخ انقذط 
 
 6002انعبو انذساعٙ 
 
 
 19 
 
 
 
 
تحضٍر المضاد الحٍوي أزثروماٌسٍن على شكل جل موضعً لاستخذامه فً علاج حة 
الشثاب و فحص تأثٍر تعض المواد المحسنة للنفارٌة على درجة نفارٌة المضاد الحٍوي 
 
 
 
 
يقذيخ يٍ انطبنت ٔنٛذ ٕٚعف كبيم 
 
 
 
خبيعخ انعهٕو ٔ انزكُٕنٕخٛب الأسدَٛخ / ثكبنٕسٕٚط طٛذنخ 
 
 
 
 
قذيذ ْزِ انشعبنخ اعزكًبلا نًزطهجبد دسخخ انًبخغزٛش 
فٙ 
انزكُٕنٕخجب انزطجٛقٛخ ٔ انظُبعٛخ 
 
 
 
 
 
 
ثشَبيح انذساعبد انعهٛب فٙ انزكُٕنٕخٛب انزطجٛقٛخ ٔ انظُبعٛخ 
كهٛخ انعهٕو ٔ انزكُٕنٕخٛب 
 
خبيعخ انقذط 
 
 
 
 6002كبٌَٕ انثبَٙ 
 
 29 
 
 
 
عًبدح انذساعبد انعهٛب 
خبيعخ انقذط 
 فهغطٍٛ –انقذط 
 
 
 
 
 
 
تحضٍر المضاد الحٍوي أزثروماٌسٍن على شكل جل موضعً لاستخذامه فً علاج حة 
الشثاب و فحص تأثٍر تعض المواد المحسنة للنفارٌة على درجة نفارٌة المضاد الحٍوي 
 
 
 
 
 
ٔنٛذ ٕٚعف كبيم : إعذاد 
 
 
 
 
 
سعبنخ يبخغزٛش 
 
انذكزٕس إثشاْٛى أنكٛبنٙ :  انًششف
 
 
 
 
 
  6002
